284 related articles for article (PubMed ID: 23967231)
1. Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer.
Coe BP; Thu KL; Aviel-Ronen S; Vucic EA; Gazdar AF; Lam S; Tsao MS; Lam WL
PLoS One; 2013; 8(8):e71670. PubMed ID: 23967231
[TBL] [Abstract][Full Text] [Related]
2. EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair.
Koyen AE; Madden MZ; Park D; Minten EV; Kapoor-Vazirani P; Werner E; Pfister NT; Haji-Seyed-Javadi R; Zhang H; Xu J; Deng N; Duong DM; Pecen TJ; Frazier Z; Nagel ZD; Lazaro JB; Mouw KW; Seyfried NT; Moreno CS; Owonikoko TK; Deng X; Yu DS
Oncogene; 2020 Jun; 39(25):4798-4813. PubMed ID: 32457468
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2.
Poirier JT; Gardner EE; Connis N; Moreira AL; de Stanchina E; Hann CL; Rudin CM
Oncogene; 2015 Nov; 34(48):5869-78. PubMed ID: 25746006
[TBL] [Abstract][Full Text] [Related]
4. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer.
Sato T; Kaneda A; Tsuji S; Isagawa T; Yamamoto S; Fujita T; Yamanaka R; Tanaka Y; Nukiwa T; Marquez VE; Ishikawa Y; Ichinose M; Aburatani H
Sci Rep; 2013; 3():1911. PubMed ID: 23714854
[TBL] [Abstract][Full Text] [Related]
5. EZH2 promotes E2F-driven SCLC tumorigenesis through modulation of apoptosis and cell-cycle regulation.
Hubaux R; Thu KL; Coe BP; MacAulay C; Lam S; Lam WL
J Thorac Oncol; 2013 Aug; 8(8):1102-6. PubMed ID: 23857401
[TBL] [Abstract][Full Text] [Related]
6. In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer.
Santos M; Martínez-Fernández M; Dueñas M; García-Escudero R; Alfaya B; Villacampa F; Saiz-Ladera C; Costa C; Oteo M; Duarte J; Martínez V; Gómez-Rodriguez MJ; Martín ML; Fernández M; Viatour P; Morcillo MA; Sage J; Castellano D; Rodriguez-Peralto JL; de la Rosa F; Paramio JM
Cancer Res; 2014 Nov; 74(22):6565-6577. PubMed ID: 25252918
[TBL] [Abstract][Full Text] [Related]
7. A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells.
Poulsen TT; Pedersen N; Juel H; Poulsen HS
Cancer Gene Ther; 2008 Sep; 15(9):563-75. PubMed ID: 18421308
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
[TBL] [Abstract][Full Text] [Related]
9. Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase.
Ott M; Litzenburger UM; Sahm F; Rauschenbach KJ; Tudoran R; Hartmann C; Marquez VE; von Deimling A; Wick W; Platten M
PLoS One; 2012; 7(10):e47663. PubMed ID: 23077658
[TBL] [Abstract][Full Text] [Related]
10. EZH2-specific microRNA-98 inhibits human ovarian cancer stem cell proliferation via regulating the pRb-E2F pathway.
Liu T; Hou L; Huang Y
Tumour Biol; 2014 Jul; 35(7):7239-47. PubMed ID: 24771265
[TBL] [Abstract][Full Text] [Related]
11. CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter.
Qiu Z; Zhu W; Meng H; Tong L; Li X; Luo P; Yi L; Zhang X; Guo L; Wei T; Zhang J
Theranostics; 2019; 9(16):4717-4729. PubMed ID: 31367252
[No Abstract] [Full Text] [Related]
12. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.
Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM
Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893
[TBL] [Abstract][Full Text] [Related]
13. EZH2 regulates cancer cell migration through repressing TIMP-3 in non-small cell lung cancer.
Xu C; Hou Z; Zhan P; Zhao W; Chang C; Zou J; Hu H; Zhang Y; Yao X; Yu L; Yan J
Med Oncol; 2013 Dec; 30(4):713. PubMed ID: 24132606
[TBL] [Abstract][Full Text] [Related]
14. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Byers LA; Wang J; Nilsson MB; Fujimoto J; Saintigny P; Yordy J; Giri U; Peyton M; Fan YH; Diao L; Masrorpour F; Shen L; Liu W; Duchemann B; Tumula P; Bhardwaj V; Welsh J; Weber S; Glisson BS; Kalhor N; Wistuba II; Girard L; Lippman SM; Mills GB; Coombes KR; Weinstein JN; Minna JD; Heymach JV
Cancer Discov; 2012 Sep; 2(9):798-811. PubMed ID: 22961666
[TBL] [Abstract][Full Text] [Related]
15. YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer.
Horie M; Saito A; Ohshima M; Suzuki HI; Nagase T
Cancer Sci; 2016 Dec; 107(12):1755-1766. PubMed ID: 27627196
[TBL] [Abstract][Full Text] [Related]
16. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive genomic profiles of small cell lung cancer.
George J; Lim JS; Jang SJ; Cun Y; Ozretić L; Kong G; Leenders F; Lu X; Fernández-Cuesta L; Bosco G; Müller C; Dahmen I; Jahchan NS; Park KS; Yang D; Karnezis AN; Vaka D; Torres A; Wang MS; Korbel JO; Menon R; Chun SM; Kim D; Wilkerson M; Hayes N; Engelmann D; Pützer B; Bos M; Michels S; Vlasic I; Seidel D; Pinther B; Schaub P; Becker C; Altmüller J; Yokota J; Kohno T; Iwakawa R; Tsuta K; Noguchi M; Muley T; Hoffmann H; Schnabel PA; Petersen I; Chen Y; Soltermann A; Tischler V; Choi CM; Kim YH; Massion PP; Zou Y; Jovanovic D; Kontic M; Wright GM; Russell PA; Solomon B; Koch I; Lindner M; Muscarella LA; la Torre A; Field JK; Jakopovic M; Knezevic J; Castaños-Vélez E; Roz L; Pastorino U; Brustugun OT; Lund-Iversen M; Thunnissen E; Köhler J; Schuler M; Botling J; Sandelin M; Sanchez-Cespedes M; Salvesen HB; Achter V; Lang U; Bogus M; Schneider PM; Zander T; Ansén S; Hallek M; Wolf J; Vingron M; Yatabe Y; Travis WD; Nürnberg P; Reinhardt C; Perner S; Heukamp L; Büttner R; Haas SA; Brambilla E; Peifer M; Sage J; Thomas RK
Nature; 2015 Aug; 524(7563):47-53. PubMed ID: 26168399
[TBL] [Abstract][Full Text] [Related]
18. EZH2: not EZHY (easy) to deal.
Deb G; Singh AK; Gupta S
Mol Cancer Res; 2014 May; 12(5):639-53. PubMed ID: 24526064
[TBL] [Abstract][Full Text] [Related]
19. VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy.
Riquelme E; Suraokar M; Behrens C; Lin HY; Girard L; Nilsson MB; Simon G; Wang J; Coombes KR; Lee JJ; Hong WK; Heymach J; Minna JD; Wistuba II
Clin Cancer Res; 2014 Jul; 20(14):3849-61. PubMed ID: 24850841
[TBL] [Abstract][Full Text] [Related]
20. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Bracken AP; Pasini D; Capra M; Prosperini E; Colli E; Helin K
EMBO J; 2003 Oct; 22(20):5323-35. PubMed ID: 14532106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
